Amgen announces positive top-line results from phase III ADVANCE study of apremilast in mild-to-moderate plaque psoriasis

Study (n=595) showed apremilast 30mg BD achieved statistically significant improvement, vs. placebo, in primary endpoint of static Physician's Global Assessment (sPGA) response [score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline] at week 16.


Biospace Inc.